Does DAROLUTAMIDE Cause Interstitial lung disease? 50 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 50 reports of Interstitial lung disease have been filed in association with DAROLUTAMIDE (NUBEQA). This represents 1.5% of all adverse event reports for DAROLUTAMIDE.
50
Reports of Interstitial lung disease with DAROLUTAMIDE
1.5%
of all DAROLUTAMIDE reports
10
Deaths
21
Hospitalizations
How Dangerous Is Interstitial lung disease From DAROLUTAMIDE?
Of the 50 reports, 10 (20.0%) resulted in death, 21 (42.0%) required hospitalization, and 1 (2.0%) were considered life-threatening.
Is Interstitial lung disease Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for DAROLUTAMIDE. However, 50 reports have been filed with the FAERS database.
What Other Side Effects Does DAROLUTAMIDE Cause?
Fatigue (384)
Death (361)
Hot flush (203)
Asthenia (173)
Prostatic specific antigen increased (156)
Off label use (133)
Neuropathy peripheral (127)
Diarrhoea (122)
Dizziness (122)
Rash (116)
What Other Drugs Cause Interstitial lung disease?
METHOTREXATE (3,049)
RITUXIMAB (2,458)
PEMBROLIZUMAB (2,113)
PREDNISONE (1,850)
CYCLOPHOSPHAMIDE (1,725)
NIVOLUMAB (1,538)
AMIODARONE (1,421)
DOXORUBICIN (1,352)
ETANERCEPT (1,267)
ADALIMUMAB (1,250)
Which DAROLUTAMIDE Alternatives Have Lower Interstitial lung disease Risk?
DAROLUTAMIDE vs DARUNAVIR
DAROLUTAMIDE vs DARUNAVIR ETHANOLATE
DAROLUTAMIDE vs DARUNAVIR\RITONAVIR
DAROLUTAMIDE vs DASABUVIR
DAROLUTAMIDE vs DASABUVIR\OMBITASVIR HEMINONAHYDRATE\PARITAPREVIR\RITONAVIR